1. Introduction
===============

Nonalcoholic fatty liver disease (NAFLD), defined as the presence of hepatic steatosis in the absence of secondary causes, is emerging as a public health issue worldwide, with a global pooled prevalence, by imaging, of 25.24% (95% confidence interval \[CI\]: 22.10--28.65%) among general population.^\[[@R1]\]^ NAFLD includes a spectrum of diseases ranging from simple steatosis to nonalcoholic steatohepatitis (NASH), and to advanced fibrosis and cirrhosis and hepatocellular carcinoma, causing considerable liver-related morbidity and mortality.^\[[@R2]\]^ Accumulated evidence has indicated that NAFLD could be regarded as part of or, indeed, a hepatic manifestation of metabolic syndrome associated with metabolic risk factors such as obesity, diabetes mellitus, and dyslipidemia.^\[[@R3],[@R4]\]^

The association between NAFLD and type 2 diabetes mellitus (T2DM) has been well established, which could be explained by the insulin-resistance and compensatory hyperinsulinemia progressing to defective lipid metabolism and hepatic triglyceride (TG) accumulation in NAFLD or to β-cell dysfunction in T2DM.^\[[@R5]\]^ Compared with nondiabetic subjects, patients with T2DM appear to have an increased risk of developing NAFLD and certainly have a heightened risk of developing advanced liver diseases, such as fibrosis, cirrhosis, and hepatocellular carcinoma.^\[[@R6]--[@R8]\]^ Furthermore, NAFLD in T2DM may lead to a higher risk of developing cardiovascular disease and diabetic vascular complications, independently of other known risk factors.^\[[@R9],[@R10]\]^ In this regard, an accurate and reliable estimate of the prevalence of NAFLD in T2DM patients is important as it can help service providers to predict the number of subjects who may develop NAFLD, and hence implement intervention strategies to cope with the problem.^\[[@R11],[@R12]\]^

Notably, the prevalence of T2DM has been increasing rapidly over the past 2 decades worldwide. For example, it increased from 10.6% in 1989 to 32.1% in 2009 among the Saudi population,^\[[@R13]\]^ which stimulated a growing research interest in NAFLD among T2DM population. However, there was a great disparity across studies in the estimated prevalence of NAFLD in T2DM patients, ranging from 45% to 80%.^\[[@R14],[@R15]\]^ This variation may be associated with the sample characteristics and the techniques used to make the diagnosis of NAFLD.^\[[@R16]\]^ Therefore, this meta-analysis aimed to explore the pooled prevalence of NAFLD in T2DM patients by synthesizing the reported data.

2. Methods
==========

2.1. Ethical approval
---------------------

Ethical approval was not required for this study, given that this was a meta-analysis, which utilized published data.

2.2. Search strategy
--------------------

This meta-analysis was carried out based on the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. A literature search of the electronic databases of PubMed, Web of Science, Embase, Chinese National Knowledge Infrastructure (CNKI), and Wanfang was carried out from their inception to July 2017. MeSH terms were used to identify relevant studies. Specifically, for the databases of PubMed and Web of Science, search term was: ("Non-alcoholic Fatty Liver Disease" \[MeSH\]) AND "Diabetes Mellitus, Type 2" \[MeSH\]; for the database of Embase, search term was: "nonalcoholic fatty liver"/mj AND "noninsulin dependent diabetes mellitus"/mj; and for the Chinese databases of CNKI and Wanfang, a combination of the MeSH terms of ![](medi-96-e8179-i001.jpg) and ![](medi-96-e8179-i002.jpg) was used. The reference lists of full articles were also reviewed.

2.3. Eligibility criteria
-------------------------

Studies were included in this meta-analysis if they were observational studies focusing on T2DM patients; provided a definition for the diagnosis of NAFLD; reported screening for alcohol excess and excluding other causes of liver diseases, such as viral hepatitis B or C; provided information about the sample size and the prevalence of NAFLD in T2DM; and were written in English or Chinese. In addition, if duplicated data were observed across studies, the earlier publication was included and, for longitudinal studies, baseline NAFLD prevalence in T2DM was included. Reviews, case-reports, comments, or book chapters were excluded from this meta-analysis. Besides, consistent with previous meta-analyses aimed at estimating the pooled prevalence, studies with a sample size of \<300 were excluded since such sample size may lead to liable prevalence.^\[[@R17]--[@R19]\]^

2.4. Data extraction
--------------------

Two investigators (WD and LY) independently assessed the eligibility of articles and extracted data from eligible articles. Any discrepancies between them were resolved by consensus. In particular, the following data were extracted: first author, year of publication, region, study design, sample source (facility-based or population-based), mean (standard deviation \[SD\]) age of the whole T2DM sample (if mean \[SD\] age of the whole T2DM sample was not reported, then mean \[SD\] age of the NAFLD patients in the whole T2DM sample was presented), diagnostic criteria of NAFLD, number of T2DM patients with NAFLD, sample size, prevalence of NAFLD in T2DM, and study quality. Furthermore, if available, data on gender, obesity, hypertension, dyslipidemia, diabetic retinopathy (DR), coronary heart disease (CHD), chronic kidney disease (CKD), and chronic obstructive pulmonary disease (COPD) were extracted for performing subgroup analyses. Full data for this study are available upon request to the corresponding author.

2.5. Quality assessment
-----------------------

In accordance with previous meta-analyses focusing on observational studies, the Agency for Healthcare Research and Quality (AHRQ) was used to evaluate the quality of eligible studies.^\[[@R20],[@R21]\]^ AHRQ is an 11-item instrument with response options Yes/No/Unclear for each item. According to the scoring guideline, the response of "Yes" is scored "1," and the response of "No" or "Unclear" is scored "0." Thus, the total score for this instrument ranges from 0 to 11, with a total score from 0 to 3, 4 to 7, and 8 to 11 indicating low quality, moderate quality, and high quality, respectively.

2.6. Statistical analyses
-------------------------

Statistical analyses for this meta-analysis were performed using the R statistical software version 3.4.1. Heterogeneity was evaluated using the Cochran *Q* test and quantified using the *I*^2^ statistic.^\[[@R22]\]^ The pooled prevalence of NAFLD in T2DM patients, presented as percentage with corresponding 95% CI, was estimated using Freeman-Tukey double arcsine method by a random-effects model when significant heterogeneity was observed (*P* ≤ .10 and *I*^2^ \> 50%). Otherwise, a fixed-effects model was used.^\[[@R23]\]^ Sensitivity was evaluated by the effect of excluding low-quality articles on the stability of the pooled prevalence.^\[[@R24],[@R25]\]^ Publication bias was assessed using both Begg test and Egger test, and an Egger funnel plot for asymmetry was presented.^\[[@R17],[@R26]\]^ Subgroup analyses, defined as differences in gender, obesity, hypertension, dyslipidemia, DR, CHD, CKD, and COPD, were performed to identify the possible sources of heterogeneity. Chi-square (χ^2^) tests were used to assess the differences across subgroups.^\[[@R24],[@R27]\]^ All tests were 2-sided and a *P* value of \<.05 was considered significant.

3. Results
==========

3.1. Search results
-------------------

A total of 3341 articles were initially searched in this study. Of these, 124 full articles were shortlisted for eligibility assessment. Among the 124 articles, 48 were excluded for not reporting the prevalence of NAFLD in T2DM patients, 28 were excluded due to a sample size of \<300, 18 were excluded for neither reporting excluding other causes of liver diseases nor reporting screening for alcohol excess, and 6 were excluded for repeated data. Finally, 24 eligible articles were included in this study (Fig. [1](#F1){ref-type="fig"}).

![Flow chart of study identification and selection.](medi-96-e8179-g001){#F1}

3.2. Study characteristics
--------------------------

Table [1](#T1){ref-type="table"} displays the characteristics of the 24 eligible studies conducted in 6 countries. A total of 35,599 T2DM patients were involved, of which 20,264 were identified with NAFLD. Also, among the 24 eligible studies, 3 were longitudinal and 21 were cross-sectional; 1 was community-based and 23 were facility-based; and 1 used the aminotransferase level from blood sample to make the diagnosis of NAFLD and 23 used ultrasound imaging. Moreover, according to the AHRQ quality assessment, 9 were considered low quality, 13 moderate quality, and 2 high quality.

###### 

Characteristics of eligible studies.

![](medi-96-e8179-g002)

3.3. Pooled prevalence of NAFLD in T2DM patients
------------------------------------------------

The reported prevalence of NAFLD in T2DM patients among the eligible studies ranged from 29.6%^\[[@R45]\]^ to 87.1%.^\[[@R35]\]^ Because significant heterogeneity (*I*^2^ = 99.0%, *P* \< .001) was observed among the eligible studies, a random-effects model was used to estimate the pooled prevalence. Thus, the pooled prevalence of NAFLD in T2DM patients was 59.67% (95% CI: 54.31--64.92%). Figure [2](#F2){ref-type="fig"} presents the details.

![Forest plot presenting the prevalence of NAFLD in T2DM patients. NAFLD = nonalcoholic fatty liver disease, T2DM = type 2 diabetes mellitus.](medi-96-e8179-g003){#F2}

3.4. Sensitivity analysis and publication bias
----------------------------------------------

After excluding 9 articles with low quality, the pooled prevalence of NAFLD in T2DM increased slightly from 59.67% (95% CI: 54.31--64.92%) to 59.75% (95% CI: 52.76--66.54%), indicating low sensitivity of this meta-analysis. Besides, both the Begg test (*z* = 0.744, *P* = .457) and Egger test (*t* = 0.774, *P* = .447) showed low possibility of publication bias, and an Egger funnel plot for asymmetry was presented (Fig. [3](#F3){ref-type="fig"}).

![Egger funnel plot of the 24 eligible studies for this meta-analysis.](medi-96-e8179-g004){#F3}

3.5. Subgroup analyses
----------------------

Table [2](#T2){ref-type="table"} shows the results of subgroup analyses. The pooled prevalence of NAFLD in male and female T2DM patients was 60.11% (95% CI: 53.63--66.41%) and 59.35% (95% CI: 53.28--65.28%), respectively. The pooled prevalence of NAFLD in T2DM patients with and without obesity was 77.87% (95% CI: 65.51--88.14%) and 55.74% (95% CI: 30.35--79.63%), respectively. Furthermore, the pooled prevalence of NAFLD in T2DM patients with and without hypertension was 66.50% (95% CI: 57.63--74.82%) and 55.78% (95% CI: 49.06--62.39%), respectively.

###### 

Subgroup analyses of NAFLD in T2DM patients.

![](medi-96-e8179-g005)

Subgroup analyses also indicated that the prevalence of NAFLD in T2DM differed by gender, obesity, hypertension, dyslipidemia, CHD, and CKD (*P* \< .05). Specifically, the prevalence of NAFLD was significantly higher in T2DM patients with male gender (vs female gender), obesity (vs without obesity), hypertension (vs without hypertension), dyslipidemia (vs without dyslipidemia), CHD (vs without CHD), and CKD (vs without CKD). Besides, the heterogeneity was high in the whole population and most subgroups. However, the heterogeneity was quite low when estimating the pooled prevalence of NAFLD in T2DM patients with CKD (*I*^2^ = 0.0, *P* = .375) and without COPD (*I*^2^ = 0.0, *P* = .460).

4. Discussion
=============

This meta-analysis provides the first quantitatively pooled prevalence of NAFLD in T2DM patients. Twenty-four eligible studies with a total of 35,599 T2DM patients were included, of which 20,264 were identified with NAFLD. The reported prevalence of NAFLD in T2DM patients ranged from 29.6%^\[[@R45]\]^ to 87.1%^\[[@R35]\]^ among the eligible studies, and this meta-analysis indicated that pooled prevalence of NAFLD in T2DM patients was 59.67% (95% CI: 54.31--64.92%).

The pooled prevalence of NAFLD in T2DM patients was much higher than that of hypercortisolism (3.4%, 95% CI: 1.5--5.9%), Cushing syndrome (1.4%, 95% CI: 0.4--2.9%), moderate hypoglycemia (45%, 95% CI: 34--57%), severe hypoglycemia (6%, 95% CI: 5--7%), and depression (17.6%) in T2DM patients in previous meta-analyses,^\[[@R49]--[@R51]\]^ indicating that NAFLD is highly prevalent in T2DM patients, which could be attributed to the shared metabolic risk factors between NAFLD and T2DM.^\[[@R5]\]^ The rapidly increasing prevalence of T2DM indicated in previous studies^\[[@R13],[@R52]\]^ and the high pooled prevalence of NAFLD in T2DM found in this meta-analysis significantly underscore the need for strengthening the management of T2DM, as well as the importance of early assessment of NAFLD in T2DM patients.

Subgroup analyses indicated that the prevalence of NAFLD was significantly higher in male T2DM patients than female T2DM patients. This finding is consistent with many previous studies. For example, Yi et al found that female gender was an independent protective factor for NAFLD, with the prevalence of NAFLD being 48.0% and 42.9% in male and female T2DM patients, respectively.^\[[@R14]\]^ Additionally, the prevalence of NAFLD was higher in men than women in the Third National Health and Nutrition Examination Survey of the United States, which enrolled 12,454 adults 20 to 74 years old from 1988 to 1994.^\[[@R53]\]^ Gender difference in the prevalence of NAFLD in T2DM patients could be attributed to the gender differences in hormone levels and lipid levels. Specifically, female hormones may play a potentially protective role in NAFLD,^\[[@R54]\]^ and the triglyceride/high density lipoprotein cholesterol (TG/HDLC) ratio appeared to be higher in men than women.^\[[@R14]\]^

The clinical associations of NAFLD with the element of metabolic syndrome, including obesity, hypertension, and dyslipidemia have been well established.^\[[@R33]\]^ For example, Yi et al found that body mass index and dyslipidemia were independent risk factors for NAFLD in T2DM,^\[[@R14]\]^ and Leite et al found that the occurrence of NAFLD in T2DM was associated with obesity and hypertriglyceridemia.^\[[@R16]\]^ Additionally, Ding et al found that T2DM patients with NAFLD had significantly higher levels of systolic blood pressure and diastolic blood pressure than T2DM patients without NAFLD.^\[[@R39]\]^ Based on these findings, it is deduced that NAFLD may be a hepatic manifestation of metabolic syndrome.^\[[@R3],[@R4]\]^ Consistently, this study found that the prevalence of NAFLD in T2DM patients differed significantly with differences in sample characteristics, including obesity, hypertension, and dyslipidemia. Insulin resistance, which is highly shared in the element of metabolic syndrome, could, to a large extent, account for the associations of obesity, dyslipidemia, and hypertension with NAFLD in T2DM.^\[[@R44]\]^ In this regard, integrated assessment and treatment strategies targeting obesity, dyslipidemia, hypertension, and NAFLD in T2DM patients are warranted.

Among the eligible studies exploring the association between microvascular complications and NAFLD, Kim et al found that the occurrence of DR and NAFLD were negatively correlated in Korean T2DM patients,^\[[@R40]\]^ whereas Wu et al found contradictory result in Chinese T2DM patients.^\[[@R44]\]^ This meta-analysis did not observe a significant association between DR and NAFLD by pooling the data of these 2 studies. Given the limited number of the included studies, more relevant studies with different ethnic populations are needed. However, significant association between CHD, an important component of macrovascular complications, and NAFLD in T2DM was observed in this study. It is suggested by Lu et al that this association may be explained by alanine aminotransferase (ALT), since the occurrence of these 2 diseases were both significantly associated with elevated ALT levels in T2DM.^\[[@R28]\]^

Additionally, subgroup analyses indicated that the prevalence of NAFLD differed significantly in T2DM patients with and without CKD. Targher et al found that the association between CKD and NAFLD in T2DM was independent of a wide range of confounding factors.^\[[@R10]\]^ However, the causal link between CKD and NAFLD remains unclear, and it is hypothesized by Targher et al that this association may be explained by the release of several pathogenic mediators from the liver, such as the elevated reactive oxygen species and increased advanced glycated end-products.^\[[@R10]\]^ More multicenter prospective studies with large sample size are needed to clarify the association between NAFLD and CKD.

Although this meta-analysis included 24 eligible studies, some limitations still need to be acknowledged. First, the heterogeneity in the whole population and most subgroups was high. However, the inclusion criteria of a sample size of at least 300 would enhance the representability of the samples in the included studies and hence obtain a more reliable pooled prevalence by this meta-analysis. Second, the majority of the eligible studies made the diagnosis of NAFLD by ultrasound imaging. Though previous studies have shown that the specificity and sensitivity of ultrasound imaging in detecting NAFLD were high,^\[[@R55]\]^ the diagnosis of NAFLD was not confirmed by liver biopsy in most original studies, which is the gold standard. Therefore, some incorrect classification of participants with and without NAFLD on the basis of ultrasound imaging remains a possibility. Third, the sample source for most eligible studies was facility-based (ie, hospitalized patients and diabetic clinic patients) rather than population-based, which may cause selection bias when estimating the prevalence of NAFLD in T2DM patients. Therefore, more community-based studies are warranted. Fourth, though several studies indicated that adolescents were also likely to suffer from NAFLD and T2DM,^\[[@R56]\]^ and age was not a restriction for this study, it was worth noting here that all samples included in this meta-analysis appeared to consist of adults, with mean ages from 52 to 70. Therefore, whether the findings of this study could be replicated to adolescents remains unclear. Also, though several studies indicated that age may be related to the occurrence of NAFLD in T2DM,^\[[@R28]\]^ subgroup analysis according to age was unable to perform, since very few eligible studies categorized age using consistent cutoff points.

5. Conclusions
==============

The pooled prevalence of NAFLD in T2DM patients was 59.67% (95% CI: 54.31--64.92%). For male and female T2DM patients, the pooled prevalence of NAFLD was 60.11% (95% CI: 53.63--66.41%) and 59.35% (95% CI: 53.28--65.28%), respectively. The prevalence of NAFLD in T2DM patients differed by gender, obesity, hypertension, dyslipidemia, CHD, and CKD. The findings of this study significantly underline the need for early assessment of NAFLD and the importance of strengthening the management of NAFLD in T2DM patients. Furthermore, more population-based studies with diverse sample characteristics are warranted.
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